Peter M. Villiger

ORCID: 0000-0002-8859-9964
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Systemic Lupus Erythematosus Research
  • Vasculitis and related conditions
  • Rheumatoid Arthritis Research and Therapies
  • Reproductive System and Pregnancy
  • Pregnancy and Medication Impact
  • Spondyloarthritis Studies and Treatments
  • Otitis Media and Relapsing Polychondritis
  • Systemic Sclerosis and Related Diseases
  • Urticaria and Related Conditions
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Autoimmune and Inflammatory Disorders Research
  • Cytokine Signaling Pathways and Interactions
  • Psoriasis: Treatment and Pathogenesis
  • Osteoarthritis Treatment and Mechanisms
  • Musculoskeletal synovial abnormalities and treatments
  • T-cell and B-cell Immunology
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Inflammatory Myopathies and Dermatomyositis
  • Cell Adhesion Molecules Research
  • Renal Diseases and Glomerulopathies
  • Musculoskeletal pain and rehabilitation
  • Inflammatory mediators and NSAID effects
  • Immunodeficiency and Autoimmune Disorders
  • Ocular Diseases and Behçet’s Syndrome

University of Bern
2015-2024

University Hospital of Bern
2014-2023

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2022

Hôpital Beau-Séjour
2004-2022

BFF Bern
2022

Kantonsspital Graubünden
2013-2021

University Hospital of Zurich
2021

University of Zurich
2021

Medical University of Vienna
2008-2020

University Hospital Schleswig-Holstein
2020

Since the publication of European League Against Rheumatism (EULAR) recommendations for management large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which potential to change care therefore supporting need update original recommendations.Using EULAR standardised operating procedures EULAR-endorsed recommendations, task force undertook a systematic literature review sought opinion from 20 experts 13 countries. We...

10.1136/annrheumdis-2019-215672 article EN Annals of the Rheumatic Diseases 2019-07-03

Abstract Objective To determine the diagnostic value of sonography in patients with suspected carpal tunnel syndrome (CTS). Methods We conducted a prospective study 110 wrists 74 consecutive CTS who had been referred to tertiary care center. determined largest cross‐sectional area median nerve at tunnel. Because lack universally accepted reference standard, we first examined association conduction. Then, compared standard based on combination conduction studies and signs symptoms. Sonography...

10.1002/art.20723 article EN Arthritis & Rheumatism 2005-01-01

To analyse the performance of a new M. tuberculosis-specific interferon gamma (IFNgamma) assay in patients with chronic inflammatory diseases who receive immunosuppressive drugs, including tumour necrosis factor alpha (TNFalpha) inhibitors.Cellular immune responses to antigens ESAT-6, CFP-10, TB7.7 were prospectively studied 142 consecutive treated for rheumatic conditions. Results compared tuberculin skin tests (TSTs). Association both risk factors latent tuberculosis infection (LTBI) and...

10.1136/ard.2007.070789 article EN Annals of the Rheumatic Diseases 2007-07-21

Abstract This study analyzes the expression of monocyte chemoattractant protein-1 (MCP-1) by inflamed synovial tissue and defines its regulation in cultured synoviocytes. Synoviocytes from patients with rheumatoid arthritis osteoarthritis express 0.7-kb MCP-1 mRNA. Stimulation synoviocytes IL-1, TNF-alpha, LPS, platelet-derived growth factor, transforming factor-beta-1, but not basic fibroblast factor causes a marked increase mRNA levels. Expression gene is inducible activators protein...

10.4049/jimmunol.149.2.722 article EN The Journal of Immunology 1992-07-15

Objective. To examine whether the G-to-A polymorphism at position −308 in promoter of tumour necrosis factor-α (TNFα) gene influences therapeutic response to TNFα-blockers patients with rheumatoid arthritis (RA), psoriatic (PsA) and ankylosing spondylitis (AS). Methods . A total 54 RA, 10 PsA 22 AS were genotyped by polymerase chain reaction for TNFα polymorphism. They treated infliximab ( n = 63), adalimumab 10) or etanercept 13). Clinical was assessed after 24 weeks Disease Activity Score...

10.1093/rheumatology/kel175 article EN Lara D. Veeken 2006-05-23

Injury to cartilage is a recognized sequela of neutrophil activation in arthritic joints. This study examined the possibility that chondrocytes may play direct role intraarticular activation. We demonstrate IL-1 beta-stimulated primary and subcultured human articular chondrocytes, express gene for potent chemotactic activating cytokine, IL-8. Expression IL-8 mRNA also inducible by TNF-alpha LPS and, lesser degree, chondrocyte growth factor, transforming factor-beta, but not platelet-derived...

10.4049/jimmunol.148.2.466 article EN The Journal of Immunology 1992-01-15

<h3>Objective</h3> To study the influence of tumour necrosis factor (TNF) antagonists on spermatogenesis in a cohort patients with spondyloarthritis (SpA). <h3>Patients and methods</h3> Semen samples 26 SpA were analysed according to WHO 1999 guidelines without TNF blocking agents (infliximab, etanercept or adalimumab). Results compared semen 102 healthy volunteers. <h3>Results</h3> Sperm abnormalities found 10/11 anti-TNF therapy. The sperm these 11 had significantly poorer motility...

10.1136/ard.2009.127423 article EN Annals of the Rheumatic Diseases 2010-07-07

Objective To prospectively evaluate histopathologic, blood cellular, serologic, and clinical changes in response to abatacept treatment patients with primary Sjögren's syndrome (SS). Methods Blood, saliva, minor salivary gland biopsy samples were obtained before after the last of 8 doses 11 SS patients. The histologic data evaluated numbers lymphocytic foci B T cell subtypes (CD20+, CD3+, CD4+, CD8+). FoxP3+ regulatory cells measured FoxP3:CD3 ratio was calculated. Histologic compared...

10.1002/acr.22052 article EN Arthritis Care & Research 2013-06-05

During pregnancy, patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA) can experience active disease, which might be influenced by adjustment of treatment around conception. The aim this study was to identify possible risk factors disease flares during pregnancy evaluate the effect in pregnant experiencing a flare.Pregnant RA axSpA were prospectively followed before, during, after pregnancy. Disease activity analyzed regard medication.Among 136 patients, occurred 29%...

10.1186/s13075-017-1269-1 article EN cc-by Arthritis Research & Therapy 2017-03-20

To analyse magnetic resonance angiographic (MRA) vessel wall signals from a randomized controlled trial of tocilizumab (TCZ) to treat GCA.Participants were assigned in 2:1 ratio receive either TCZ + glucocorticoids (GCs) or placebo GC infusions at 4-week intervals for 52 weeks. GCs started 1 mg/kg/day, then tapered 0.1 mg/kg/day week 12 and thereafter down zero. Patients with initial positive MRA findings underwent control weeks 52. Vessel scored 0 (normal) 3 (intense late enhancement)....

10.1093/rheumatology/key015 article EN Lara D. Veeken 2018-02-16

Abstract Objective It is currently unknown how long GCA should be treated with tocilizumab. In the first randomized controlled trial, biologic agent was stopped after 52 weeks. We therefore studied what proportion of patients relapsed, when relapses occurred and whether factors might predict relapse tocilizumab treatment discontinuation. Methods All in arm who had received a 52-week were evaluated. case lasting remission, magnetic resonance angiography (MRA) performed sera taken to search...

10.1093/rheumatology/kez091 article EN Lara D. Veeken 2019-02-22

To analyse pregnancy outcome and delivery mode in patients with RA axial spondyloarthritis (axSpA) relation to disease activity anti-rheumatic drugs. Patients axSpA were compared age-matched healthy controls (HCs) respect mode. Disease (DAS28, ASDAS, CRP) medication use of was assessed once at each trimester. ORs 95% CI calculated univariate multivariate regression models. We analysed 244 pregnancies, which 96 occurred RA, 78 70 HCs. The adjusted analysis showed that pregnant women had a...

10.1093/rheumatology/key053 article EN Lara D. Veeken 2018-03-26

Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) used patients with SSc for various organ manifestations mainly to ameliorate progression SSc-ILD. Data on everyday IS prescription patterns and clinical courses function during after therapy are scarce. We analysed fulfilling American College Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria SSc-ILD at least one report IS. Types IS,...

10.1186/s13075-018-1517-z article EN cc-by Arthritis Research & Therapy 2018-01-30
Coming Soon ...